NEOANTIGENICITY OF RIBOFLAVIN AND LIGHT TREATED RBCS IN BABOONS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 进行本研究以确定使用核黄素和UV光的Mirasol病原体减少技术（MPRT）处理的RBC是否会引发免疫应答。 第二个目的是评估狒狒中MPRT处理的RBC的存活和恢复。 将未经处理或经Mirasol处理的自体RBC与明矾佐剂一起配制，并注射到相应的狒狒供体中。 在未处理或MPRT处理的狒狒中均未观察到对RBC的抗体应答。 接下来，用CR 51标记未处理和MPRT处理的RBC，并输注回供体。 存活和恢复动力学在未处理和MPRT处理的狒狒中非常相似。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study was conducted to determine whether an immune response would be elicited to RBCs treated with the Mirasol pathogen reduction technology (MPRT) using Riboflavin and UV light. The second objective was to assess the survival and recovery of MPRT treated RBCs in baboons. Autologous RBC's either untreated or Mirasol-treated were formulated with alum adjuvant and was injected into the respective baboon donors. No antibody response to RBCs was observed either in the untreated or MPRT treated baboons. Next, untreated and MPRT treated RBCs were labeled with CR51 and infused back into the donors. Survival and recovery kinetics were quite similar in the untreated and MPRT treated baboons.